VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine in VaccineBusiness Wire • 01/15/21
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B VaccineBusiness Wire • 12/23/20
Are Options Traders Betting on a Big Move in VBI Vaccines (VBIV) Stock?Zacks Investment Research • 12/14/20
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B VaccineBusiness Wire • 12/07/20
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond JamesBusiness Wire • 12/02/20
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B VaccineBusiness Wire • 12/01/20
VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines AgencyBusiness Wire • 11/23/20
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBMBusiness Wire • 11/19/20
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic InfectionBusiness Wire • 11/18/20
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual MeetingBusiness Wire • 11/09/20
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate UpdateBusiness Wire • 11/02/20
VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-ConferenceBusiness Wire • 10/15/20
VBI Vaccines, Inc. (VBIV) Gains But Lags Market: What You Should KnowZacks Investment Research • 10/09/20
VBI Vaccines, Inc. (VBIV) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/29/20